Understanding the Cardio-Renal Syndromes
|
|
- Frederica Harmon
- 5 years ago
- Views:
Transcription
1 Understanding the Cardio-Renal Syndromes The Cardio-Renal axis: an underestimated player in cardiovascular diseases ESC Congress Munich 27/08/2012 Alberto Palazzuoli Department of Internal Medicine Cardiology Unit S. Maria alle Scotte Hospital, University of Siena Italy
2 Heart and Kidney: Dangerous liaison Regulation of volume and BP (Na + and H 2 O) Electrolyte and acid-base balance Hormonal function (Erythropoiesis Vascular tone) Blood purification from metabolic waste products Regulation of perfusion pressure and flow to periphery Electrical activity depend on electrolytes and acid-base Contractility depend on O 2, volume, electrolytes, toxin Hormonal function (ANP - BNP) ADQI Acute Dialysis Quality Initiative Consensus Group ADQI
3 The Cardio-Renal Syndrome (CRS) How can we define it? Is an early diagnosis of AKI important? What is the exact significance of WRF? What is the link between heart and kidney? What is the prevalent pathophysiological mechanism?? ADQI Acute Dialysis Quality Initiative Consensus Group ADQI
4 Common Characteristics of the Cardiorenal Syndrome Heart Reduced renal blood flow and GFR Increased venous congestio n Increased vascular resistance RAAS activity Diuretic resistance Albuminuri a Increased BUN Fluid overload Tubular and glomerula r damage Inflammato ry activation, endothelial dysfunction Anemia Kidney Palazzuoli, Ronco Heart Fail Rev 2011
5 Cardio Renal Syndromes acute Cardio-Renal Reno-Cardiac chronic Secondary Cardio-Renal Ronco, C. et al. J Am Coll Cardiol 2008
6
7 The cardiorenal syndrome in heart failure Damman K et al. Prog Cardiovas Dis. 2011
8 When the Creatinine Rises Patient can t go home Diuretic doses are often decreased RAAS inhibitors are often discontinued Other medications are renally dosed Inotropes may be initiated PA catheter may be placed Foley catheter may be placed Renal advise may be ordered (and is rarely helpful)
9 Eventi/ 1000 persone/ anno Eventi/ 1000 persone/ anno Primary Outcome Myocardial Infarct Cardiovascular Death in pz. with creatinine <1.4 mg/dl or 1.4 mg/dl Eventi/ 1000 persone/ anno Eventi/ 1000 persone/ anno 80 Primary outcome Myocardial infarction All patients Placebo 0 Creatinine < 1.4 mg/dl Creatinine 1.4 mg/dl 0 Creatinine <1.4 mg/dl Creatinine 1.4 mg/dl Ramipril 40 Cardiovascular death 60 All death Creatinine <1.4 mg/dl Creatinine 1.4 mg/dl 0 Creatinine <1.4 mg/dl Creatinine 1.4 mg/dl HOPE Trial, Ann Intern Med, 2001
10 Demographic and Baseline Characteristics by Kidney Function Stage in ADHERE Database Parameter I (n=10,660) Kidney Function Stage II (n=32,433) III (n=51,533) IV (n=15,553) V (n=82769) p Age, mesn (SD), y ) 70.1 (14.7) 75.7 (12.0) 76.3 (11.6) 67.4 (14.7) <.0001 Atrial fibrillation <.0001 Diabetes <.0001 Hypertension <.0001 Peripheral vascular disease <.0001 Renal insufficiency <.0001 BNP, pg/ml, n ,243 22, ns Hb, means (SD), g/dl 13.0 (2.6) 13.0 (2.5) 12.3 (2.5) 11.4 (2.3) 11.5 (2.5) <.0001 Accross stage using chi-square tests for categoric variables and analysis of variance for continuos variables Heywood JT et al, J Card Fail, 2007
11 Main Clinical Outcomes by egfr Quartiles: OPTIME-HF Quartile 1 (n=234) Quartile 2 (n=235) Quartile 3 (n=234) Quartile 4 (n=234) egfr, ml min m (75-94) 60 (55-65) 45 (42-48) 29 (25-33) <0.01 Primary end point, d 5 (4-10) 6 (4-13) 7 (4-14) 8 (5-17) <0.01 Deaths, n(%) In hospital * 1 (0.44) 3 (1.3) 8(3.4) 16 (6.8) <0.01 At 60 days 10 (4.3) 9 (3.9) 25 (10.8) 44 (19) <0.01 Hazards ratio (95% CI) Referent 0.9 ( ) 2.63 ( ) 4.73 ( ) Readmissions/death within 60 days, n (%) 53 (22.9) 71 (31) 93 (40.1) 106 (45.3) <0.01 Odds ratio (95% CI) Referent 1.51 (1-2.29) 2.25 ( ) 2.8 ( ) P *Odds ratios for in-hospital death are questionable because of the small numbers of events and thus are not presented Raw percentages of patients followed up to the 60-day visit. Cox proportional-hazards regression using indicator variables was used to analyze 60- day death rate. Categorical variables were analyzed with logistic regression. Probability values represent overall relationship with egfr as a continuous variable for regression models. All individual quartiles vs lowest quartile, p<0.05 Klein M et al, Circ Heart Fail, 2008
12 Relationship Between Renal Parameters and 6-Months Outcomes Time to Death Time to Death or Rehospitalization HR* 95% CI P Value HR* 95% CI p Value Baseline SCr < < Baseline egfr < < Discharge SCr < < Discharge egfr < > 0.3 mg/dl SCr > 25% 2 egfr *Hazard ratio (HR) calculated per 0.3-mg/dl increments in serum creatinine (SCr) and per 10-ml/min decrements in estimated glomerular filtration rate (egfr). Worsening renal function, defined as: 1) an increase in SCr 0.3 mg/dl; and 2) a decrease in egfr 25% from baseline to discharge, is treated as a dichotomous variable. CI confidence interval. Nohria et al ESCAPE Trial JACC 2008
13 % Events Kaplan-Meier curves for CV mortality/morbidity stratified by egfr: SAVE study 60% 50% 40% 30% 20% 10% 0% egfr <60, placebo egfr <60, captopril egfr >60, placebo egfr >60, captopril 1 year 2 year 3 year 4 year Years post-mi Tokmakova et al SAVE Study Circulation 2008
14 cumulative incidence cumulative incidence Kaplan-Meier plot of cumulative incidence of cardiovascular death or unplanned admission to hospital for the management of worsening CHF in patients with reduced LVEF and preserved LV systolic function < > years < > years Hillege et al CHARM Circulation 2006
15 What is the real Risk when IR is associated to CHF % HR 1.56 (p= 0.001) Any impairment 51 HR 2.31 (p= 0.001) Moderate/severe impairment 24 No impairment Mortality: 15% for every 0.5 mg/dl increase in creatinine 7% for every 10 ml/min decrease in egfr Smith GL et al, J Am Coll Cardiol 2006
16 Cumulative survival (death or HF admission) WRF outcome during hispitalization and at early and post discharge: COACH study 1.0 WRF in-hospital WRF 0-6 months WRF 6-12 months No WRF WRF Follow-up time (days) Damman K et al. Eur J Heart Fail 2009
17 Clinical Characteristics and Outcomes of Patients With Improvement in Renal Function During the Treatment of Decompensated Heart Failure Testani JM et al. Journal of Cardiac Fail 2011
18 Potential mechanisms of increased mortality in WRF Marker of more decompensated HF Relationship due to cardio-renal interaction Discontinuation of common treatments Greater prevalence of coexistent diseases
19
20 The traditional concept of WRF in acute HF Decrease in cardiac output Arterial underfilling Systemic and Renal vasocostriction Decreased perfusion pressure Increased neuro-hormonal activity Glomerular and interstitial damage
21 Acute CRS Type 1 Hemodynamically mediated damage Acute Heart Disease or Procedures Acute decompensation Ischemic insult Coronary angiography Cardiac surgery Caspase activation Apoptosis Decreased CO Humoral signalling BNP Exogenous factors Contrast media ACE inhibitors Diuretics Sympathetic Activation Humorally mediated damage RAA activation, Na + H2O retention, vasoconstriction Hormonal factors Immune mediated damage Monocyte Activation Endothelial activation Decreased perfusion Toxicity Vascocostriction. Natriuresis Increased venous pressure Cytokine secretion Caspase activation Apoptosis Renal hypoperfusion Reduced oxygen delivery Necrosis / apoptosis Decreased GFR Resistance to ANP/BNP BIOMARKERS KIM-1 Cystatin-C N-GAL Creatinine Acute Kidney Injury ADQI Acute Dialysis Quality Initiative Consensus Group ADQI
22 Impact of changes in blood pressure during the treatment of acute decompensated heart failure on renal and clinical outcomes Characteristics overall cohort no SBP-reduction yes SBP-reduction P Demographics Age (years) 56.4± ± ± Males 74,1% 74,1% 74,1% Functional status/ ejection fraction NYHA class (mean class) 3.9± ± ± Six minut walk (feet) 422± ± ± MVO2 (ml/kg/min) 10.1± ± ± Ejection fraction 19.5± ± ± Systolic blood pressure 101.5± ± ±11.7 <0.001* Admission to discharge change in blood pressure Absolute 4.3± ± ±11.5 <0.001* Relative 2.8± ± ±8.2 <0.001* Laboratory findings GFR(mL/min/1.73 m 2 ) 56.9± ± ± * *Significant P- value. Testani et al. Eur J of Heart Fail 2011
23 Influence of renal dysfunction phenotype on mortality in the setting of cardiac dysfunction: analysis of three randomized controlled trials * LBC Low BUN creatinine HBC High BUN creatinine Testani JM et al. Eur J Heart Fail 2011
24 Blood urea nitrogen as biomarker of neurohormonal activation Kazory A Am J Cardiol 2010
25 Relationship Between Neurohormones and LVEF and GFR c GFR c LVEF Univariate r Multivariate Univariate Multivariate Norepinephrine 0.28 < NS Epinephrine NS Dopamine 0.23 < NS Renin <0.001 NS Aldosterone NS ANP 0.35 <0.001 < < N-terminal ANP 0.53 <0.001 < <0.001 <0.001 Endothelin NS Epinine NS NS Hillege HL et al. Circulation 2000
26 Adaptive response to renal hypoperfusion in HF Ruggenenti P et al. Eur H J 2011
27 VENOUS CONGESTION AND WORSENING RENAL FUNCTION Mullens et al, JACC, 2009
28 Relation among renal dysfunction and Congestion in CHF Damman K et al Eur J Heart Fail 2010
29 Is WRF as ominous prognostic sign in AHF patients? The role of congestion Variable Death, Transplant, or HF Rehospitalization Univariable HR (95% CI) * Univariable P Value Multivariable HR (95% CI) * Multivariable P Value Previous HF , CKD 1.69 < Laboratory characteristics Plasma hemoglobin, 0.59 < Serum sodium, admission 0.6 < Serum sodium, discharge Congestion and WRF. 1: Yes WRF and yes congestion 5.35 < (0.88, 2.2) : No WRF and yes congestion : Yes WRF and no congestion Reference: No WRF and no congestion Ref Ref Metra et al Circ Heart Fail 2012
30 Changes in renal parameters and Intra abdominal pressure Mullens W et al J Am Coll Cardiol 2008
31 Changes in IAP and serum creatinine in patients underwent to paracentesis or ultrafiltration Mullens W et al J Cardiac Fail 2008
32 Fluid overload: redistribution and accumulation mechanisms Increased vascular resistance Increased arterial stiffness leads to hightened afterload Fluid overload redistribution Increased venous return and preload Reduced capacitance in veins Cotter G et al Eur J Heart Fail 2008
33 Interaction among fluid overload cardiac output and mean blood pressure Haemodinamic control (Guyton) Volume expansion Increased cardiac output Total body autoregolation Increased peripheral resistance Increased blood pressure Pressure natriuresis Renal failure Cardiorenal connection NO-ROS Dysbalance Sympathetic Nervous Systolic Activation Renin Angiotensin System Activation Inflammation Heart failure Cardiovascular damage Bongartz L G et al. Eur Heart J 2005
34 Cardiac output Pulmonary hypertension RV failure Peripheral vascular resistance Venous congestion Arterial Underfilling Renal venous pressure Intra-abdominal pressure Neurohormonal Activation Renal interstitial pressure SNS activity RAAS activity AVP release? Myocardial depressant factor Renal hemodinamics and renal salt/water excretion Tang WW et al. Heart 2010
35 The The Perfect Storm Sorm
36 ADQI Creatinine Criteria Urine Output Criteria ADQI Risk Increased creatinine x1.5 or Creatinine increase > 0.3 mg/dl UO <0.5 ml/kg/h x 6 hr High Sensitivity Injury Creatinine increase x 2 UO <0.5 ml/kg/h x 12 hr Failure Creatinine increase x 3 or creatinine 4 mg/dl (Acute rise of 0.5 mg/dll UO <0.3 ml/kg/h x 24 hr or anuria x 12 hrs High Specificity Loss ESRD Persistent ARF** = complete loss of renal function > 4 weeks End Stage Renal Disease ADQI Acute Dialysis Quality Initiative Consensus Group ADQI
37 Mortality by RIFLE Class Mortality Non-AKI Risk Injury Failure 13 studies, n >71,000 patients ADQI Acute Dialysis Quality Initiative Consensus Group ADQI
38 Acute Reno-Cardiac syndome: epidemiology Heterogeneity of AKI different methods to define AKI different risk profile in the enrolled population few studies reporting cardiac events clinical information about cardiac conditions at baseline POOR CLINICAL CHARACTERIZATION AND DEFINITION Cruz D et al Heart Fail Rev 2011
39 Causes of Acute Kidney Injury Preexisting renal insufficiency Glomerulonephritis Rhabdomyolysis Red. effective arterial volume Exogenous toxins Red. extracellular volume Cardio-Renal Impaired renal microcirculation Drug toxicity SIRS / sepsis ADQI Acute Dialysis Quality Initiative Consensus Group ADQI
40 Neurormonal increase leads to Diuretic-Resistance Glomerul Norepinephrine (and endothelin) reduce blood flow and GRF Proximal Tubul Ang II increases Na resorbtion Collector Duct Aldosteron increases Na resorbtion Krämer et al. Am J Med. 1999;106:90.
41 Acute RCS Type 3 Decreased GFR Na + H 2 O retention Volume expansion Increased pre-load Hypertension Acute Kidney Injury Sympathetic Activation RAA activation,, vasoconstriction Acute Heart Dysfunction Glomerular diseases Interstitial diseases Acute tubular necrosis Acute pyelonephritis Acute urinary obstruction Caspase activation Apoptosis Humoral Signalling Electrolyte, acid-base & coagulation imbalances Monocyte Activation Endothelial activation Cytokine secretion Caspase activation Apoptosis Acute decompensation Acute heart failure Ischemic insult Arrythmias Decreased CO BIOMARKERS Troponin Myoglobin MPO BNP ADQI Acute Dialysis Quality Initiative Consensus Group ADQI
42 DEGREES OF RENAL AND CARDIOVASCULAR DISEASES Renal terminal insufficiency Insuff. Renal Chronic ( FG) End Stage Progression Refractory heart failure Cardiovascular Events Age, obesity Diabetes hypertension Renal Disease Albuminuria Proteinuria Starting At risk LV Insufficiency Age, obesity Diabetes hypertension Cardiovascular Disease Sarnak MJet al, Am J Kidney Dis, 2000
43 Common factors for heart and kidney diseases Ronco C et al JACC 2012 (in press)
44 Parenchimal disease Treatment for HF Artery disease Renal dysfunction Neuroendocrine and cytokine activation Congestion and hypoperfus. Cleland JG et al Heart Fail Rev 2012
45 RAAS Effects In Renal and Cardiac diseases Renal effects sodium and water reabsrobtion Efferent arterioles constriction proteinuria increase glomerular sclerosis and tubular fibrosis Reduced medullary blood flow blood flow redistribution idrostatic and oncotic pressure Cardiovascular effects vascular muscle cell proliferation and thickness Increase blood pressure Left ventricular hypertrophy and fibrosis Increase atherosclerosis activity neuro hormonal overdrive impairment endothelial function Decrease fibrinolitic acitivity with plateled aggregation
46 Inflammatory activation: cardiac and renal interaction Inflammation Arteries and Veins Endothelial dysf & vascular stiffness Myocardium Contractility fibrosis & apoptosis Kidney Na retention & fluid intake Tubulo glomerular damage Congestion Colombo P et al Heart Fail Rev 2012
47 The role of Inflammation in Cardio-Renal syndrome Endothelial cells activation DAMP signaling Complement activation Leukocite infiltration Inflammation Platelet activation increase prthrombotic and Pro coagulative processes Capillary obstruction Peristent ischemia Rosner MH et al. Semin Nephrol 2012
48 Tubular damage in chronic systolic heart failure is Relationship between CKD and urinary NAG, NGAL and KIM-1. associated with reduced survival independent of glomerular filtration rate. Damman K et al. Heart 2010
49 Clinical outcome of renal tubular damage in CHF Adjusted for age, gender, egfr, and UACR Multivariable adjusted a Variable Multivariable HR P-value P CR Multivariable HR P-value P CR lognag (per SD) Mortality HF hospitalizations 1.38 ( ) 1.22 ( ) ( ) ( ) logkim-1 (per SD) Mortality HF hospitalizations 1.17 ( ) 1.13 ( ) ( ) ( ) logngal (per SD) Mortality HF hospitalizations 1.24 ( ) 1.01 ( ) ( ) ( ) 0.85 Damman K et al. Eur H J 2011
50 CONCLUSIONS The cardiorenal syndrome is heterogeneous group of pathophysiological entities and the clinical course depends on the prevalent mechanism by which the renal function is impaired There is priority to better understand the patophysiologic link between Heart and Kidney, and to know the more sensitive and specific parameters able to identify primitive organ damage their mechanism and significance WRF is a mirror of different clinical situation and it should be evaluated taking into account previous cardio-renal damages as well as hemodynamic and non hemodynamic conditions Pathophysiologic processes are different in CRS subtypes and involve several actors (hemodynamic, neurohormones, inflammation, fluid overload) We need to focus on research agenda designed to recognize the vicious circle of pathological heart-kidney interactions and mechanisms in every clinical condition Better assessment of congestion, fluid redistribution, neuro-endocrine overdrive, tubular and glomerular damage, could improve our understanding in CRS
51
Cardiorenal Syndrome
SOCIEDAD ARGENTINA DE CARDIOLOGIA Cardiorenal Syndrome Joint session ESC-SAC ESC Congress 2012, Munich César A. Belziti Hospital Italiano de Buenos Aires I have no conflicts of interest to declare Cardiorenal
More informationPathophysiology of Cardio-Renal Interactions
Pathophysiology of Cardio-Renal Interactions Claudio Ronco, MD Department of Nephrology St. Bortolo Hospital International Renal Research Institute Vicenza - Italy Pathophysiology of Cardio-Renal Interactions
More informationCardiorenal Syndrome
Cardiorenal Syndrome Peenida Skulratanasak, M.D. Division of Nephrology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University Definition of Cardiorenal syndrome (CRS) Structural
More informationHeart Failure and Renal Disease Cardiorenal Syndrome
Advanced Heart Failure: Clinical Challenges Heart Failure and Renal Disease Cardiorenal Syndrome 17 th Apr 2015 Ju-Hee Lee, M.D Cardiovascular Center, Chungbuk National University Hospital Chungbuk National
More informationThe Cardiorenal Syndrome in Heart Failure
The Cardiorenal Syndrome in Heart Failure Van N Selby, MD Assistant Professor of Medicine Advanced Heart Failure Program, UCSF October 9, 2015 Disclosures None 1 Cardiorenal Syndrome (CRS) A pathophysiologic
More informationPivotal Role of Renal Function in Acute Heart failure
Pivotal Role of Renal Function in Acute Heart failure Doron Aronson MD, FESC Department of Cardiology RAMBAM Health Care Campus Haifa, Israel Classification and definitions of cardiorenal syndromes CRS
More informationHeart Failure and Renal Failure. Gerasimos Filippatos, MD, FESC, FHFA President HFA
Heart Failure and Renal Failure Gerasimos Filippatos, MD, FESC, FHFA President HFA Definition Epidemiology Pathophysiology Management (?) Recommendations for NHLBI in cardiorenal interactions related to
More informationRuolo dei Marcatori Bioumorali nello scompenso cardiaco
Ruolo dei Marcatori Bioumorali nello scompenso cardiaco Head Emergency Medicine Sant Andrea Hospital Director Postgraduate School of Emergency Medicine Faculty od Medicine and Psycology Sapienza University
More informationCardiorenal syndrome. Sofie Gevaert. Ghent University Hospital, Belgium
Cardiorenal syndrome Sofie Gevaert Ghent University Hospital, Belgium Disclosures Consultancy Astra Zeneca Boegringer MSD Novartis 68 y old man, ADHF ICMP, ejection fraction 35 %: progressive dyspnea,
More informationTHE KIDNEY IN HYPOTENSIVE STATES. Benita S. Padilla, M.D.
THE KIDNEY IN HYPOTENSIVE STATES Benita S. Padilla, M.D. Objectives To discuss what happens when the kidney encounters low perfusion To discuss new developments and clinical application points in two scenarios
More informationTreating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment
ESC 2012 27Aug - 3Sep, 2012, Munich, Germany Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment Marco Metra, MD, FESC Cardiology University
More informationOvercoming the Cardiorenal Syndrome
Overcoming the Cardiorenal Syndrome October 29, 2016 Randall C Starling MD MPH FACC FESC FHFSA FHFA Professor of Medicine Heart & Vascular Institute Cleveland Clinic Lerner College of Medicine Cleveland
More informationRecognizing and Treating Patients with the Cardio-Renal Syndrome
Recognizing and Treating Patients with the Cardio-Renal Syndrome Joachim H. Ix, MD, MAS, FASN Professor of Medicine Chief; Division of Nephrology-Hypertension University of California San Diego 1 Conflicts
More informationCardio-Renal Syndrome in Acute Heart Failure:
Cardio-Renal Syndrome in Acute Heart Failure: Target for Therapy Marvin A. Konstam, M.D. Research support and/or consulting relevant to this lecture: Merck, Otsuka, Johnson & Johnson; Amgen; Cardiokine
More informationPearls in Acute Heart Failure Management
Pearls in Acute Heart Failure Management Best Practices Juan M. Aranda Jr., M.D. Professor of Medicine Medical Director of Heart Failure/ Transplant Program University of Florida College of Medicine Disclosures:
More informationPathophysiology of Cardio-Renal Interactions
European Society of Cardiology 2011 Paris-France Pathophysiology of Cardio-Renal Interactions Claudio Ronco, MD Department of Nephrology St. Bortolo Hospital International Renal Research Institute Vicenza
More informationCardiorenal Syndrome Prof. Dr. Bülent ALTUN Hacettepe University Faculty of Medicine Department of Internal Medicine Division of Nephrology
Cardiorenal Syndrome Prof. Dr. Bülent ALTUN Hacettepe University Faculty of Medicine Department of Internal Medicine Division of Nephrology Heart and Kidney The kidney yin dominates water, The heart yang
More informationDoppler ultrasound, see Ultrasonography. Magnetic resonance imaging (MRI), kidney oxygenation assessment 75
Subject Index Acidemia, cardiorenal syndrome type 3 146 Acute Dialysis Quality Initiative (ADQI) acute kidney injury biomarkers, see Acute kidney injury; specific biomarkers cardiorenal syndrome, see specific
More informationCase Presentation. This presentation is the intellectual property of the author. Contact them for permission to reprint and/or distribute.
Worsening Renal Function in Heart Failure Patients Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationBiomarkers, the Kidney and the Heart: Acute Kidney Injury
Biomarkers, the Kidney and the Heart: Acute Kidney Injury 12th Annual Conference on Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices San Diego May 13, 2016 Ravindra
More informationPractical Points in Cardiorenal Syndrome
Practical Points in Cardiorenal Syndrome Vichai Senthong, MD. Cardiovascular Unit, Faculty of Medicine Khon Kaen university HFCT Annual Scientific Meeting June 16, 2017, Eastin Grand Sathorn Hotel, Bangkok
More informationThe Triple Threat. Cardiac Care in the NT Annual Workshop 2017 is proudly supported by:
The Triple Threat DR KELUM PRIYADARSHANA FRACP CONSULTANT NEPHROLOGIST ROYAL DARWIN HOSPITAL Cardiac Care in the NT Annual Workshop 2017 is proudly supported by: Pathogenesis Diabetes CKD CVD Diabetic
More informationNovel Approaches for Recognition and Management of Life Threatening Complications of AKI and CKD: Focus on Acute Cardiorenal Syndromes
Novel Approaches for Recognition and Management of Life Threatening Complications of AKI and CKD: Focus on Acute Cardiorenal Syndromes Peter A. McCullough, MD, MPH Baylor University Medical Center, Dallas
More informationState of the Art: acute heart failure Is it just congestion?
ESC CONGRESS 2017 Barcelona, 26. 30. August 2017 State of the Art: acute heart failure Is it just congestion? S.B. Felix, FESC Klinik für Innere Medizin B Ernst-Moritz-Arndt-Universität Greifswald 1456
More informationHeart Failure and Cardio-Renal Syndrome 1: Pathophysiology. Biomarkers of Renal Injury and Dysfunction
CRRT 2011 San Diego, CA 22-25 February 2011 Heart Failure and Cardio-Renal Syndrome 1: Pathophysiology Biomarkers of Renal Injury and Dysfunction Dinna Cruz, M.D., M.P.H. Department of Nephrology San Bortolo
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationDefining and Managing the Cardiorenal Syndrome in Acute Decompensated Heart Failure. Barry M. Massie Professor of Medicine UCSF
Defining and Managing the Cardiorenal Syndrome in Acute Decompensated Heart Failure Barry M. Massie Professor of Medicine UCSF DISCLOSURES Consulting fees: Merck-Novacardia Novartis Bristol Myers Squibb
More informationFluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI)
Fluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI) Robert W. Schrier, MD University of Colorado School of Medicine Denver, Colorado USA Prevalence of acute renal failure in Intensive
More informationPathophysiology: Heart Failure
Pathophysiology: Heart Failure Mat Maurer, MD Irving Assistant Professor of Medicine Outline Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology Heart Failure: Definitions
More informationThe right heart: the Cinderella of heart failure
The right heart: the Cinderella of heart failure Piotr Ponikowski, MD, PhD, FESC Medical University, Centre for Heart Disease Clinical Military Hospital Wroclaw, Poland none Disclosure Look into the Heart
More informationMonitoring of Renal Function in Heart Failure
Monitoring of Renal Function in Heart Failure Adriaan A. Voors, cardiologist The Netherlands Disclosures AAV received consultancy fees and/or research grants from: Alere, Bayer, Cardio3Biosciences, Celladon,
More informationCardiorenal Biomarkers and Heart Failure. Nicholas Wettersten, MD April 7 th, 2017
Cardiorenal Biomarkers and Heart Failure Nicholas Wettersten, MD April 7 th, 2017 Disclosures Still none, but looking for some Acute Kidney Injury Biomarkers 547 in 2015 4112 as of March 2017 Case 1 60
More informationAcute heart failure syndromes: clinical challenges. Pathophysiology. ESC Congress August. Paris, France. Marco Metra
ESC Congress 2011 27-31 August. Paris, France. Acute heart failure syndromes: clinical challenges. Pathophysiology Marco Metra Cardiology, Dept. Of experimental and applied medicine. University of Brescia.
More informationLe sindromi cardio renali G. VESCOVO
Le sindromi cardio renali G. VESCOVO G. VESCOVO MD, PhD, FESC Dip. Medicina Interna VICENZA Le sindromi cardio renali Consensus Conference Prevalence of CVD Any CVD: 80 million (1 in 3) Htn: 73 million
More informationUpdate on Cardiorenal Syndrome: A Clinical Conundrum
Advances in Peritoneal Dialysis, Vol. 27, 2011 Eric J. Chan, 1 Kevin C. Dellsperger 1 3 Update on Cardiorenal Syndrome: A Clinical Conundrum Our understanding of the cardiorenal syndrome continues to progress.
More informationThe Who, How and When of Advanced Heart Failure Therapies. Disclosures. What is Advanced Heart Failure?
The Who, How and When of Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center Lebanon, NH May 20, 2013 Joseph G. Rogers,
More informationOutline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies
Outline Pathophysiology: Mat Maurer, MD Irving Assistant Professor of Medicine Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology : Definitions An inability of the
More informationState-of-the-Art: Treatment of Renal Dysfunction in Heart Failure. W. H. Wilson Tang, MD Cleveland Clinic, U.S.A.
State-of-the-Art: Treatment of Renal Dysfunction in Heart Failure W. H. Wilson Tang, MD Cleveland Clinic, U.S.A. Heart Failure Exacerbates Renal Insufficiency ADHERE Registry: Prevalence of CKD by egfr
More informationΟξεία καρδιακή ανεπάρκεια: Ποιες παράμετροι συμβάλλουν στη διαστρωμάτωση κινδύνου των ασθενών;
Οξεία καρδιακή ανεπάρκεια: Ποιες παράμετροι συμβάλλουν στη διαστρωμάτωση κινδύνου των ασθενών; Γ. Φιλιππάτος, MD, FACC, FESC, FCCP Επ. Καθηγητής Καρδιολογίας Πανεπ. Αθηνών Clinical Outcomes in Patients
More informationBiomarkers for optimal management of heart failure. Cardiorenal syndrome. Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland
Biomarkers for optimal management of heart failure Cardiorenal syndrome Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland Presenter Disclosure Information V-P Harjola The following
More informationObjectives 6/14/2016. Cardiorenal Syndrome: Critical Link Between Heart and Kidney
Cardiorenal Syndrome: Critical Link Between Heart and Kidney Chris M. Bell, ACNP Cardiology Associates of North Mississippi Objectives Review the 5 Subtypes of the Cardiorenal Syndrome (CRS) Discuss the
More informationContrast Induced Nephropathy
Contrast Induced Nephropathy O CIAKI refers to an abrupt deterioration in renal function associated with the administration of iodinated contrast media O CIAKI is characterized by an acute (within 48 hours)
More informationAcute Kidney Injury for the General Surgeon
Acute Kidney Injury for the General Surgeon UCSF Postgraduate Course in General Surgery Maui, HI March 20, 2011 Epidemiology & Definition Pathophysiology Clinical Studies Management Summary Hobart W. Harris,
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationClinical efficacy of ultrafiltration in the treatment of acute decompensated heart failure with diuretic resistance.
Biomedical Research 2017; 28 (14): 6155-6159 ISSN 0970-938X www.biomedres.info Clinical efficacy of ultrafiltration in the of acute decompensated heart failure with diuretic resistance. Jian Zhang, Qi
More informationThe Art and Science of Diuretic therapy
The Art and Science of Diuretic therapy Dr. Fayez EL Shaer Associate Professour of cardiology Consultant cardiologist MD, MSc, PhD, CBNC, NBE FESC, ACCP, FASNC,HFA KKUH, KFCC Heart failure: fluid overload
More informationEditorial Staying in the Pink of Health for Patients with Cardiorenal Anemia Requires a Multidisciplinary Approach
Editorial Staying in the Pink of Health for Patients with Cardiorenal Anemia Requires a Multidisciplinary Approach Anemia and Heart Failure Ragavendra R. Baliga, MD, MBA James B. Young, MD Consulting Editors
More informationDiagnosis is it really Heart Failure?
ESC Congress Munich - 25-29 August 2012 Heart Failure with Preserved Ejection Fraction From Bench to Bedside Diagnosis is it really Heart Failure? Prof. Burkert Pieske Department of Cardiology Med.University
More informationAKI: definitions, detection & pitfalls. Jon Murray
AKI: definitions, detection & pitfalls Jon Murray Previous conventional definition Acute renal failure (ARF) An abrupt and sustained decline in renal excretory function due to a reduction in glomerular
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationCardiorenal and Renocardiac Syndrome
And Renocardiac Syndrome A Vicious Cycle Cardiorenal and Renocardiac Syndrome Type 1 (acute) Acute HF results in acute kidney injury Type 2 Chronic cardiac dysfunction (eg, chronic HF) causes progressive
More informationCardiorenal Syndrome: What the Clinician Needs to Know. William T. Abraham, MD Director, Division of Cardiovascular Medicine
Cardiorenal Syndrome: What the Clinician Needs to Know William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Renal Hemodynamics in Heart Failure Glomerular
More informationIntravenous Inotropic Support an Overview
Intravenous Inotropic Support an Overview Shaul Atar, MD Western Galilee Medical Center, Nahariya Affiliated with the Faculty of Medicine of the Galilee, Safed, Israel INOTROPES in Acute HF (not vasopressors)
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationCardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center
Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationProf. Andrzej Wiecek Department of Nephrology, Endocrinology and Metabolic Diseases Medical University of Silesia Katowice, Poland.
What could be the role of renal denervation in chronic kidney disease? Andrzej Wiecek, Katowice, Poland Chairs: Peter J. Blankestijn, Utrecht, The Netherlands Jonathan Moss, Glasgow, UK Prof. Andrzej Wiecek
More informationHeart Failure Guidelines For your Daily Practice
Heart Failure Guidelines For your Daily Practice Juan M. Aranda, Jr., MD, FACC, FHFSA Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida College of Medicine
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationCopeptin in heart failure: Associations with clinical characteristics and prognosis
Copeptin in heart failure: Associations with clinical characteristics and prognosis D. Berliner, N. Deubner, W. Fenske, S. Brenner, G. Güder, B. Allolio, R. Jahns, G. Ertl, CE. Angermann, S. Störk for
More informationHyponatremia as a Cardiovascular Biomarker
Hyponatremia as a Cardiovascular Biomarker Uri Elkayam, MD Professor of Medicine University of Southern California Keck School of Medicine elkayam@usc.edu Disclosure Research grant from Otsuka for the
More informationHeart Failure. Guillaume Jondeau Hôpital Bichat, Paris, France
Heart Failure Guillaume Jondeau Hôpital Bichat, Paris, France Epidemiology Importance of PEF Europe I-PREFER study. Abstract: 2835 Prevalence of HF Preserved LV systolic Function older (65 vs 62 y, p
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Paricalcitol Capsules (ABT-358) (Zemplar ) Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationImpact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction
Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction Masahito Shigekiyo, Kenji Harada, Ayumi Okada, Naho Terada, Hiroyoshi Yoshikawa, Akira Hirono,
More informationWORSENING OF RENAL FUNCTION AFTER RAS INHIBITION IN DECOMPENSATED HEART FAILURE: CLINICAL IMPLICATIONS
WORSENING OF RENAL FUNCTION AFTER RAS INHIBITION IN DECOMPENSATED HEART FAILURE: CLINICAL IMPLICATIONS George Bakris, MD, FASH, FAHA, FASN Professor of Medicine Director, Comprehensive Hypertension Center
More informationManagement of Acute Heart Failure
Management of Acute Heart Failure Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu ADHF Treatments Goals.2 Improve symptoms.
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
More informationCopyright 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Normal Cardiac Anatomy
Mosby,, an affiliate of Elsevier Normal Cardiac Anatomy Impaired cardiac pumping Results in vasoconstriction & fluid retention Characterized by ventricular dysfunction, reduced exercise tolerance, diminished
More informationCardiovascular Protection and the RAS
Cardiovascular Protection and the RAS Katalin Kauser, MD, PhD, DSc Senior Associate Director, Boehringer Ingelheim Pharmaceutical Inc. Micardis Product Pipeline Scientific Support Ridgefield, CT, USA Cardiovascular
More informationObjectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009
Objectives Diastolic Heart Failure and Indications for Echocardiography in the Asian Population Damon M. Kwan, MD UCSF Asian Heart & Vascular Symposium 02.07.09 Define diastolic heart failure and differentiate
More informationManagement of Advanced Systolic Heart Failure. Robert W. Hull MD FACC Associate Professor of Medicine West Virginia University
Management of Advanced Systolic Heart Failure Robert W. Hull MD FACC Associate Professor of Medicine West Virginia University American College of Cardiology Foundation (ACCF) American Heart Association
More informationRRT in Advanced Heart Failure and Liver Failure When to start and when to stop?
Critical Care Medicine Apollo Hospitals RRT in Advanced Heart Failure and Liver Failure When to start and when to stop? Ramesh Venkataraman, AB (Int. Med), AB (CCM) Senior Consultant, Critical Care Medicine
More informationJournal of the American College of Cardiology Vol. 35, No. 3, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 3, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00608-7 The Prognostic
More informationΟξεία Καρδιακή Ανεπάρκεια: Κλινική εικόνα, ταξινόμηση κινδύνου & προγνωστικοί δείκτες
Οξεία Καρδιακή Ανεπάρκεια: Κλινική εικόνα, ταξινόμηση κινδύνου & προγνωστικοί δείκτες Στράτος Θεοφιλογιαννάκος, MD, PhD Ιατρείο Καρδιακής Ανεπάρκειας, Γ Πανεπιστημιακή Καρδιολογική Κλινική ΑΠΘ, ΠΓΝ Ιπποκράτειο
More informationPathophysiology: Heart Failure. Objectives
Pathophysiology: Heart Failure Mat Maurer, MD Irving Assistant Professor of Clinical Medicine Objectives At the conclusion of this seminar, learner will be able to: 1. Define heart failure as a clinical
More informationRenal Denervation. Henry Krum MBBS PhD FRACP. Centre of Cardiovascular Research & Monash University/Alfred Hospital;
Renal Denervation Henry Krum MBBS PhD FRACP Centre of Cardiovascular Research & Education in Therapeutics, Monash University/Alfred Hospital; Alfred Heart Centre, The Alfred Hospital, Melbourne Australia
More informationMedical Management of Acutely Decompensated Heart Failure. William T. Abraham, MD Director, Division of Cardiovascular Medicine
Medical Management of Acutely Decompensated Heart Failure William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Goals of Acute Heart Failure Therapy Alleviate
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationCirculation. Blood Pressure and Antihypertensive Medications. Venous Return. Arterial flow. Regulation of Cardiac Output.
Circulation Blood Pressure and Antihypertensive Medications Two systems Pulmonary (low pressure) Systemic (high pressure) Aorta 120 mmhg Large arteries 110 mmhg Arterioles 40 mmhg Arteriolar capillaries
More informationM2 TEACHING UNDERSTANDING PHARMACOLOGY
M2 TEACHING UNDERSTANDING PHARMACOLOGY USING CVS SYSTEM AS AN EXAMPLE NIGEL FONG 2 JAN 2014 TODAY S OBJECTIVE Pharmacology often seems like an endless list of mechanisms and side effects to memorize. To
More informationAcute Kidney Injury. Amandeep Khurana, MD Southwest Kidney Institute
Acute Kidney Injury Amandeep Khurana, MD Southwest Kidney Institute 66 yr white male w/ DM, HTN, CAD admitted to an OSH w/ E Coli UTI on 7/24/16, developed E Coli bacteremia and Shock (on vaso + levo)
More informationAcute Kidney Injury. I. David Weiner, M.D. Division of Nephrology, Hypertension and Transplantation University of Florida and NF/SGVHS
Acute Kidney Injury I. David Weiner, M.D. Division of Nephrology, Hypertension and Transplantation University of Florida and NF/SGVHS 374-6102 David.Weiner@medicine.ufl.edu www.renallectures.com Concentration
More informationDuring exercise the heart rate is 190 bpm and the stroke volume is 115 ml/beat. What is the cardiac output?
The Cardiovascular System Part III: Heart Outline of class lecture After studying part I of this chapter you should be able to: 1. Be able to calculate cardiac output (CO) be able to define heart rate
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationMedical Management of Acute Heart Failure
Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training
More informationMinimizing the Renal Toxicity of Iodinated Contrast
Minimizing the Renal Toxicity of Iodinated Contrast Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP Chief Academic and Scientific Officer St. John Providence Health System Detroit, MI USA Outline
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationRegulation of Body Fluids: Na + and Water Linda Costanzo, Ph.D.
Regulation of Body Fluids: Na + and Water Linda Costanzo, Ph.D. OBJECTIVES: After studying this lecture, the student should understand: 1. Why body sodium content determines ECF volume and the relationships
More informationHeart Failure. Acute. Plasma [NE] (pg/ml) 24 Hours. Chronic
Heart Failure Heart failure is the inability of the heart to deliver sufficient blood to the tissues to ensure adequate oxygen supply. Clinically it is characterized by signs of volume overload or symptoms
More informationBlood Pressure Regulation 2. Faisal I. Mohammed, MD,PhD
Blood Pressure Regulation 2 Faisal I. Mohammed, MD,PhD 1 Objectives Outline the intermediate term and long term regulators of ABP. Describe the role of Epinephrine, Antidiuretic hormone (ADH), Renin-Angiotensin-Aldosterone
More informationBlood Pressure Regulation 2. Faisal I. Mohammed, MD,PhD
Blood Pressure Regulation 2 Faisal I. Mohammed, MD,PhD 1 Objectives Outline the intermediate term and long term regulators of ABP. Describe the role of Epinephrine, Antidiuretic hormone (ADH), Renin-Angiotensin-Aldosterone
More informationImpact of Renal Dysfunction on the Outcome of Acute Myocardial Infarction
ORIGINAL ARTICLE JIACM 2010; 11(4): 277-81 Impact of Renal Dysfunction on the Outcome of Acute Myocardial Infarction Shagun Sachdeva*, NP Singh**, Renuka Saha*** Abstract The presence of coexisting conditions
More informationHeart-failure or Kidney Failure?
Heart-failure or Kidney Failure? Dr Ajith James Consultant Nephrologist Barts Health and BHRUT Mr AR 65 yrs Case Type 2 DM, IHD-MI 1998, 2003. PCI x 3. CABG 2008, HT CCF with LVEF 30% 2014. NYHA Class
More informationBeyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015
Beyond ACE-inhibitors for Heart Failure Jacob Townsend, MD NCVH Birmingham 2015 % Decrease in Mortality Current Therapy HFrEF 0% Angiotensin receptor blocker ACE inhibitor Beta blocker Mineralocorticoid
More informationUsing Lung Ultrasound to Diagnose and Manage Acute Heart Failure
Using Lung Ultrasound to Diagnose and Manage Acute Heart Failure Jennifer Martindale, MD Assistant Professor Department of Emergency Medicine SUNY Downstate/Kings County Hospital Brooklyn, NY What is acute
More informationOLOMOUC I Study M. Táborský, M. Lazárová, J. Václavík, D. Richter ESC 2012, Munich,
The effect of renal denervation in patients with advanced heart failure: OLOMOUC I Study M. Táborský, M. Lazárová, J. Václavík, D. Richter ESC 2012, Munich, 27.08.2012 Disclosures MT: honoraria Bayer,
More informationCatheter Based Denervation for Heart Failure
Catheter Based Denervation for Heart Failure David E. Kandzari, MD, FACC, FSCAI Chief Scientific Officer Director, Interventional Cardiology Piedmont Heart Institute Atlanta, Georgia david.kandzari@piedmont.org
More informationAcute Kidney Injury. APSN JSN CME for Nephrology Trainees May Professor Robert Walker
Acute Kidney Injury APSN JSN CME for Nephrology Trainees May 2017 Professor Robert Walker Kidney International (2017) 91, 1033 1046; http://dx.doi.org/10.1016/ j.kint.2016.09.051 Case for discussion 55year
More information